<?xml version='1.0' encoding='utf-8'?>
<document id="17061171"><sentence text="Antiplatelet drug resistance and drug-drug interactions: Role of cytochrome P450 3A4." /><sentence text="Antiplatelet therapy provided pivotal advances in the treatment of cardiovascular disease" /><sentence text=" Aspirin and thienopyridine, clopidogrel, is currently the treatment of choice in acute coronary syndromes and the prevention of thrombosis after coronary stent implantation"><entity charOffset="1-8" id="DDI-PubMed.17061171.s3.e0" text="Aspirin" /><entity charOffset="13-27" id="DDI-PubMed.17061171.s3.e1" text="thienopyridine" /><entity charOffset="29-40" id="DDI-PubMed.17061171.s3.e2" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.17061171.s3.e0" e2="DDI-PubMed.17061171.s3.e0" /><pair ddi="false" e1="DDI-PubMed.17061171.s3.e0" e2="DDI-PubMed.17061171.s3.e1" /><pair ddi="false" e1="DDI-PubMed.17061171.s3.e0" e2="DDI-PubMed.17061171.s3.e2" /><pair ddi="false" e1="DDI-PubMed.17061171.s3.e1" e2="DDI-PubMed.17061171.s3.e1" /><pair ddi="false" e1="DDI-PubMed.17061171.s3.e1" e2="DDI-PubMed.17061171.s3.e2" /></sentence><sentence text=" Despite the efficacy of this dual antiplatelet therapy in reduction of adverse coronary events in patients with acute coronary syndromes, complications persist in a subgroup of these patients" /><sentence text=" Emerging causes of aspirin and clopidogrel resistance may translate to increase risk for recurrent myocardial infarction, stroke, or cardiac related mortality"><entity charOffset="20-27" id="DDI-PubMed.17061171.s5.e0" text="aspirin" /><entity charOffset="32-43" id="DDI-PubMed.17061171.s5.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.17061171.s5.e0" e2="DDI-PubMed.17061171.s5.e0" /><pair ddi="false" e1="DDI-PubMed.17061171.s5.e0" e2="DDI-PubMed.17061171.s5.e1" /></sentence><sentence text=" However, the mechanism of antiplatelet drug resistance remains incompletely characterized, and a sensitive and specific assay of aspirin and clopidogrel effect that reliably predicts treatment failure has not emerged"><entity charOffset="130-137" id="DDI-PubMed.17061171.s6.e0" text="aspirin" /><entity charOffset="142-153" id="DDI-PubMed.17061171.s6.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.17061171.s6.e0" e2="DDI-PubMed.17061171.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17061171.s6.e0" e2="DDI-PubMed.17061171.s6.e1" /></sentence><sentence text=" To date, evidence supporting antiplatelet drug resistance are pharmacokinetic response variability, drug-drug interaction through competitive inhibition a specific enzymatic pathway, genetic variability, and variability in the induction of enzymatic pathway in metabolic activation of prodrugs, like clopidogrel"><entity charOffset="301-312" id="DDI-PubMed.17061171.s7.e0" text="clopidogrel" /></sentence><sentence text=" Further investigation or guidelines are needed to optimize antiplatelet treatment strategies to identify and treat patients resistant to aspirin and/or clopidogrel"><entity charOffset="138-145" id="DDI-PubMed.17061171.s8.e0" text="aspirin" /><entity charOffset="153-164" id="DDI-PubMed.17061171.s8.e1" text="clopidogrel" /><pair ddi="false" e1="DDI-PubMed.17061171.s8.e0" e2="DDI-PubMed.17061171.s8.e0" /><pair ddi="false" e1="DDI-PubMed.17061171.s8.e0" e2="DDI-PubMed.17061171.s8.e1" /></sentence><sentence text="" /></document>